2025-07-11 - Analysis Report
Okay, here's a draft report based on the information you provided.

## Eli Lilly and Co (LLY) Stock Analysis

**Ticker:** LLY
**Company Description:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (LLY):** 255.83%
*   **Cumulative Return (VOO):** 96.17%
*   **Absolute Divergence:** 158.66%
*   **Divergence Range:** Max 311.6, Min -27.3
*   **Relative Divergence:** 54.9

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the observed period. The relative divergence of 54.9 indicates that LLY's outperformance is positioned more toward the middle range of its historical outperformance relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
| ---------- | ------ | ----- | ------- | ------ | ------ |
| 2015-2017  | 10.0%  | 56.3% | -19.0%  | 0.0    | 75.8   |
| 2016-2018  | 39.0%  | 58.6% | 21.0%   | -0.1   | 103.9  |
| 2017-2019  | 50.0%  | 58.6% | 20.0%   | 0.3    | 118.0  |
| 2018-2020  | 52.0%  | 58.6% | 33.0%   | 0.1    | 151.6  |
| 2019-2021  | 106.0% | 60.6% | 57.0%   | 0.2    | 248.0  |
| 2020-2022  | 98.0%  | 64.8% | 96.0%   | 0.2    | 328.4  |
| 2021-2023  | 133.0% | 64.8% | 115.0%  | 0.3    | 523.3  |
| 2022-2024  | 150.0% | 72.2% | 124.0%  | 0.2    | 693.0  |
| 2023-2025  | 109.0% | 76.8% | 61.0%   | 0.2    | 709.8  |

**Analysis:**

*   **CAGR:**  The Compounded Annual Growth Rate is increasing over time.
*   **MDD:** The Maximum Drawdown shows increasing potential losses.
*   **Alpha:**  Alpha is very high, indicating strong performance independent of the market.
*   **Beta:**  Beta is generally low, indicating low volatility.
*   **Cap:**  Market capitalization has grown significantly.

### 2. Recent Price Action

*   **Last Price:** 790.65
*   **Previous Close:** 786.92
*   **Change:** 0.47
*   **5-Day Moving Average:** 783.31
*   **20-Day Moving Average:** 787.47
*   **60-Day Moving Average:** 780.71

**Analysis:** The stock is trading above its 5, 20, and 60-day moving averages, suggesting short-term upward momentum.  The small increase in price compared to the previous close implies a relatively stable trading day.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3373 (Low Risk)
*   **RSI:** 52.50
*   **PPO:** -0.0052
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (3 shares - Caution - MRI:0.35)
*   **Delta_Previous_Relative_Divergence:** 0.1 (+) (Short-term increase)
*   **Expected Return:** 133.6% (Over 2+ years vs. S&P 500)

**Analysis:**

*   The **MRI** suggests low market risk.
*   The **RSI** is close to neutral, not indicating overbought or oversold conditions.
*   The slightly negative **PPO** suggests some potential short-term weakness, but it's marginal.
*   The positive change in relative divergence indicates short-term upward momentum.
*   The high **Expected Return** suggests significant potential outperformance relative to the S&P 500 over the long term.

### 4. Recent News & Significant Events

*   **[2025-07-10]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-09]:** Analyst discussions on recent performance and industry/economic outlook.
*   **[2025-07-08]:** Notable stock volatility influenced by news, earnings, or executive actions.
*   **[2025-07-07]:** Market experts highlight both risks and opportunities.

**Analysis:** The news indicates increased attention on LLY due to potential impactful events, requiring investors to stay informed. Recent volatility suggests market sensitivity to news and developments.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
| ---------- | ---- | ----------- |
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2024-08-08 | 3.29 | 11.30 B$    |
| 2024-04-30 | 2.49 | 8.77 B$     |
| 2025-05-01 | 2.49 | 8.77 B$     |

**Analysis:** The most recent earnings report (2025-05-01) shows strong EPS and revenue.  There's a clear upward trend in revenue over the reported quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-03-31 | $12.73B  | 82.53%        |
| 2024-12-31 | $13.53B  | 82.24%        |
| 2024-09-30 | $11.44B  | 81.02%        |
| 2024-06-30 | $11.30B  | 80.80%        |
| 2024-03-31 | $8.77B   | 80.91%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
| ---------- | --------- | -------- |
| 2025-03-31 | $15.76B  | 17.50%   |
| 2024-12-31 | $14.19B  | 31.07%   |
| 2024-09-30 | $14.24B  | 6.81%    |
| 2024-06-30 | $13.56B  | 21.88%   |
| 2024-03-31 | $12.81B  | 17.51%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue has generally increased over the past year, with consistently high profit margins.
*   **Capital and Profitability:** Equity has grown, and ROE, while fluctuating, remains at generally healthy levels.

### 7. Overall Summary and Recommendations

Eli Lilly (LLY) exhibits strong performance characteristics:

*   **Outperformance:** Significant outperformance vs. the S&P 500.
*   **Growth:**  Strong revenue and earnings growth.
*   **Profitability:** Consistently high profit margins.
*   **Market Sentiment:**  Recent news suggests both opportunities and potential volatility.
*   **Low Risk:**  Low Market Risk Indicator.

**Recommendation:**  Based on this analysis, LLY appears to be a fundamentally strong company with significant growth potential.  The "Buy" signal from the hybrid indicator further supports a positive outlook, although the "Caution" note suggests monitoring the MRI.  Investors should be aware of the potential for volatility highlighted in the recent news.  The high expected return suggests that a long-term, buy-and-hold strategy could be beneficial. Continuous monitoring of news, earnings, and market conditions is advisable.
